The Myelin Repair Foundation chieves Phase 1 Myelin Repair Clinical Trial

Published: Jun 14, 2012

SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) today announced the achievement of a myelin repair Phase 1 clinical trial for multiple sclerosis earlier than the foundation’s goal set for 2014. By establishing its Accelerated Research Collaboration (ARC) Model to advance myelin repair treatments forward into clinical trial Phase 1 within a decade, the Myelin Repair Foundation achieved this critical milestone ahead of its goal, validating the efficiency of the ARC model to speed drug development.

Back to news